POLYMED Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹535 Cr
verified against source
Revenue YoY
12.3%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Poly Medicure delivered a mixed Q4 FY26 with 534 crore consolidated revenue (+21% YoY) but PAT of 112 crore was impacted by ~9 crore one-time provisions from recent acquisitions (Pendra, CTF). The company navigated significant headwinds including 20% raw material inflation from crude-linked costs and West Asia logistics disruptions (~6-8% revenue exposure) through 3-5% price hikes, rupee depreciation benefits, and 2.5-3 months inventory buffers. Standalone EBITDA margin came in at 27.3% for Q4. The strategic shift toward high-technology segments is showing results with infusion therapy now at 50% of revenue (down from 57%), while new verticals contribute over 50%. Management guided FY27 consolidated revenue of 2,300-2,400 crore and standalone 1,900-1,950 crore, implying 25%+ growth, with EBITDA margin guidance of 23-25% consolidated and 25-27% standalone. Capex guidance reduced to 200-225 crore as expansion projects near completion. Key risks include Chinese dumping in renal (government petition pending), Middle East logistics normalization, and margin pressure from sustained crude elevation above $100/barrel assumptions.
Colored figures show movement against the previous available record.
Guidance to track
- Implies ~25% YoY growth including full-year consolidation of Pendra and CTF, driven by domestic growth of 20%+ and international 15%+.
- Consolidated margin guided lower at 23-25% as subsidiaries currently operate at mid-teens margins, with synergy benefits expected to drive improvement to 18-20% over 2-3 years.
- Lower than FY26's 296 crore as major plant expansions (Jubbalgarh, Mitrat, Medical Park) are nearing operational completion. Focus shifting to automation to offset minimum wage increases.
- Current crude price assumption of $100-110/barrel creates 200-300 bps headwind vs FY26's 68%. Price increases (3-5%) and rupee depreciation provide partial offset. Impact expected to be negligible if crude softens.
Risks flagged
- Chinese manufacturers circumvent anti-dumping duties by routing through ASEAN (zero import duty). Management is petitioning government for counter duties. Despite 20%+ growth guidance, competition remains fierce with cost inversion against PolyMed's domestic manufacturing.
- Red Sea diversions causing shipping bottlenecks and logistics cost inflation. Demand remains intact but supply chain disruptions are delaying execution of pending orders from a region contributing 6-8% of revenue.
- CTF and Pendra operating at 12-14% EBITDA margins vs group average, dragging consolidated margins. Q4 subsidiary impact was negative 2.66 crore with calendar Q1 seasonality headwinds. Analyst pressed on receivables normalization (86 days vs 68 days YoY) with management indicating FI27 will see similar DSO levels.
- Despite 20% aggregate raw material cost increase and 3-5% price hikes taken, gross margin guidance of 66-68% implies 200-300 bps compression. Management acknowledged current business plan is built on $100-110 crude, leaving limited margin of safety if prices remain elevated.
Key quotes
- FY27 will be when initiatives we have undertaken drive synergies across the group and continue investments in higher and high-end technology segments.
- We are managing every piece and working on a lot of initiatives inside the organization. Based on where we are today, we may see some erosion on gross margin going from 68% to maybe around 66%, but this is just a present estimation.
- Our focus has been more on the clinical side. We added a lot of people on the clinical team. Now we are doing a lot of global clinical trainings and increased hospital visits internationally, which is helping us mitigate earlier challenges.
Research modules